This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Carney, M. E. Articles by Futreal, P. A. Search for Related Content PubMed PubMed Citation Articles by Carney, M. E. Articles by Maxwell, G. L. Articles by Lancaster, J. M. Articles by Gumbs, C. Articles by Marks, J. Articles by Berchuck, A. Articles by Futreal, P. A. Social Bookmarking                         What's this?

Aberrant Splicing of the TSG101 Tumor Suppressor Gene in Human Breast and Ovarian Cancers

G. Larry Maxwell, MD

Johnathan M. Lancaster, MC,BCh

Curtis Gumbs, BS

Jeffrey Marks, PhD

Departments of Obstetrics and Gynecology/Division of Gynecologic Oncology, Surgery, and Genetics, Duke University Medical Center, Durham, North Carolina

Andrew Berchuck, MD

Departments of Obstetrics and Gynecology/Division of Gynecologic Oncology, Surgery, and Genetics, Duke University Medical Center, Durham, North Carolina; Duke University Medical Center, Box 3079, Durham, NC 27710

P. Andrew Futreal, PhD

Departments of Obstetrics and Gynecology/Division of Gynecologic Oncology, Surgery, and Genetics, Duke University Medical Center, Durham, North Carolina

Objective: To determine whether large deletions or other alterations in the putative tumor suppressor gene TSG101 play a role in the molecular pathogenesis of breast and ovarian cancers.

Methods: Expression of TSG101 transcripts was examined in breast and ovarian cancers using the reverse transcriptase-polymerase chain reaction (RT-PCR), and selected transcripts were sequenced. Southern blot analysis was performed to determine whether there were genomic deletions in the TSG101 gene, and Northern blot analysis was used to examine the relative abundance of various transcripts.

Results: All the cancerous and normal breast tissue examined expressed full length 1145 base pair (bp) TSG101 transcripts. Additional truncated transcripts were seen using the RT-PCR in 57 (64%) of 89 primary breast cancers, 1 (20%) of 5 breast cancer cell lines, 3 (50%) of 6 normal breast tissues, 16 (64%) of 25 primary ovarian cancers and 1 (33%) of 3 ovarian cancer cell lines. Only the primary breast (21%) and ovarian (24%) cancers had three or more truncated transcripts. None of the normal tissues or cell lines examined had more than two aberrant transcripts. DNA sequencing revealed that the most commonly expressed truncated transcript arises because of loss of 902 bp between codons 153 and 1055. Only full length TSG101 transcripts were seen on Northern blot analysis of breast cancer cell lines, however. There was no evidence of genomic deletions in the TSG101 gene on Southern blot analysis.

Conclusion: Truncated TSG101 transcripts that probably represent splice variants are present in some breast and ovarian cancers, but there is no evidence to suggest that loss of this putative tumor suppressor gene plays a role in the molecular pathogenesis of these cancers.

Key Words: TSG101 • ovarian cancer • breast cancer • tumor suppressor gene

Journal of the Society for Gynecologic Investigation, Vol. 5, No. 5, 281-285 (1998)
DOI: 10.1177/107155769800500510


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?